Quarter Ended Jun 30, 2024
Net sales were down 5% to $110.6 million compared to $116.5 million (down 3% in constant currency).
GAAP net income attributable to common shareholders was $1.3 million, or $0.07 per diluted common share, compared to $2.4 million, or $0.12 per diluted common share.
Adjusted EBITDA down 8% to $10.4 million compared to $11.3 million.
Q2 2024 Earnings Release
For complete information regarding our financials, see our periodic filings.
Nature’s Sunshine provides over 600 products across the globe, investing in the people and world around us. No one obsesses over results like we do, and we have prioritized our environmental, social and governance efforts to become a company our shareholders can depend on. Join us as we take health to new heights.
View ESGGeographic segments: Asia, Europe, North America and Latin America/Other
Product lines: General Health, Immune, Cardiovascular, Digestive, Personal Care and Weight Management
Employees, as of December 31, 2022
As of Dec. 31, 2022 • 10-K 2022
In thousands
As of Dec. 31, 2022 • 10-K 2022
For complete information regarding our financials, see our periodic filings.
Nature’s Sunshine Products, Inc.
2901 W Blue Grass Blvd.
Lehi, UT 84043
Gateway Group
Cody Slach
T: 949-574-3860
NATR@gateway-grp.com
American Stock Transfer & Trust
40 Wall Street
New York, NY 10005
T: 800-937-5449
help@astfinancial.com